Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial-Reference-Cited by-同舟云学术

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Published:2020-11 Issue:11 Volume:31 Page:1526-1535
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Litton J.K.,Hurvitz S.A.,Mina L.A.,Rugo H.S.,Lee K.-H.,Gonçalves A.,Diab S.,Woodward N.,Goodwin A.,Yerushalmi R.,Roché H.,Im Y.-H.,Eiermann W.,Quek R.G.W.,Usari T.,Lanzalone S.,Czibere A.,Blum J.L.,Martin M.,Ettl J.

Funder

Medivation

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference15 articles.

1. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent

2. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib;Murai;Mol Cancer Ther,2014

3. PARP inhibitors: synthetic lethality in the clinic;Lord;Science,2017

4. Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers;de Bono;Cancer Discov,2017

5. A Phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO);Turner;Clin Cancer Res,2019

Cited by 209 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial;European Journal of Cancer;2024-03

2. The Current and Future Roles of Precision Oncology in Advanced Breast Cancer;Journal of Nuclear Medicine;2024-02-01

3. Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs);Cancer Treatment Reviews;2024-02

4. Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy;Frontiers in Pharmacology;2024-01-24

5. Targeted Therapies and Drug Resistance in Advanced Breast Cancer, Alternative Strategies and the Way beyond;Cancers;2024-01-22